Publication:
Antitumor efficacy of ceranib-2 with nano-formulation of PEG and rosin esters

Simple item page
dc.contributor.coauthorBen Taleb, Ali
dc.contributor.coauthorKarakus, Selcan
dc.contributor.coauthorTan, Ezgi
dc.contributor.coauthorIlgar, Merve
dc.contributor.coauthorKutlu, Ozlem
dc.contributor.coauthorKutlu, Hatice Mehtap
dc.contributor.coauthorKilislioglu, Ayben
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorGözüaçık, Devrim
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:46:44Z
dc.date.issued2021
dc.description.abstractCeranib-2 is a recently discovered, poorly water-soluble potent ceramidase inhibitor, with the ability to suppress cancer cell proliferation and delay tumor growth. However, its poor water solubility and weak cellular bioavailability hinder its use as a therapeutic agent for cancer. PEGylated rosin esters are an excellent platform as a natural polymer for drug delivery applications, especially for controlling drug release due to their degradability, biocompatibility, capability to improve solubility, and pharmacokinetics of potent drugs. In this study, stable aqueous amphiphilic submicron-sized PEG400-rosin ester-ceranib-2 (PREC-2) particles, ranging between 100 and 350 nm in a 1:1 mixture, were successfully synthesized by solvent evaporation mediated by sonication. Conclusion: Stable aqueous PEGylated rosin ester nanocarriers might present a significant solution to improve solubility, pharmacokinetic, and bioavailability of ceranib-2, and hold promises for use as an anticancer adjacent drug after further investigations.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipEuropean Union
dc.description.sponsorshipGreek national funds through the program "Support for Researchers with Emphasis on Young Researchers" [EDBM34, KE 14995] This work has been co-financed by the European Union and Greek national funds through the program "Support for Researchers with Emphasis on Young Researchers" (call code: EDBM34, KE 14995) and under the research title "Preparation and study of innovative forms of administration of pharmaceutical molecules targeting at improved pharmacological properties."
dc.description.volume2207
dc.identifier.doi10.1007/978-1-0716-0920-0_16
dc.identifier.eissn1940-6029
dc.identifier.isbn978-1-0716-0920-0
dc.identifier.isbn978-1-0716-0919-4
dc.identifier.issn1064-3745
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85094836206
dc.identifier.urihttps://doi.org/10.1007/978-1-0716-0920-0_16
dc.identifier.urihttps://hdl.handle.net/20.500.14288/14003
dc.identifier.wos691010900017
dc.keywordsCeranib-2
dc.keywordsRosin ester
dc.keywordsPegylation
dc.keywordsNanoencapsulation
dc.keywordsAnticancer smart drug-delivery
dc.keywordsSphingolipid metabolism
dc.keywordsBiodegradable polymers
dc.keywordsCell-survival
dc.keywordsGlobal burden
dc.keywordsCancer
dc.keywordsCeramide
dc.keywordsPegylation
dc.keywordsStress
dc.keywordsSphingosine-1-phosphate
dc.language.isoeng
dc.publisherHumana Press Inc
dc.relation.ispartofSupramolecules In Drug Discovery and Drug Delivery: Methods and Protocols
dc.subjectBiochemical research methods
dc.subjectChemistry
dc.subjectMedicinal
dc.subjectPharmacology
dc.subjectPharmacy
dc.titleAntitumor efficacy of ceranib-2 with nano-formulation of PEG and rosin esters
dc.typeBook Chapter
dspace.entity.typePublication
local.contributor.kuauthorGözüaçık, Devrim
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscoveryd437580f-9309-4ecb-864a-4af58309d287

Files

Collections

Publications without Fulltext